Who is sponsoring NCT06593353?

NCT06593353 is sponsored by University of Washington.

What drugs are being tested in NCT06593353?

Interventions in NCT06593353: Systems Analysis and Improvement Approach (SAIA).

What condition does NCT06593353 study?

NCT06593353 studies Opioid Use Disorder, Opioid Use Disorders.

Is NCT06593353 still recruiting?

NCT06593353 is currently recruiting now. Last updated 4 December 2025.

Last reviewed 2025-12-04 · How we verify

NCT06593353: SAIA-MOUD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Systems Analysis and Improvement to Optimize Opioid Use Disorder Care Quality and Continuity for Patients Exiting Jail

Recruiting now NA Last updated 4 December 2025

What this trial tests

NA trial testing Systems Analysis and Improvement Approach (SAIA) in Opioid Use Disorder in 4,165 participants. Currently enrolling.

Timeline

21 November 2024

Primary endpoint
31 March 2028

30 June 2028

Quick facts

Lead sponsor	University of Washington
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	health services research
Enrollment	4,165
Start date	21 November 2024
Primary completion	31 March 2028
Estimated completion	30 June 2028
Sites	1 location across United States

Drugs / interventions tested

Systems Analysis and Improvement Approach (SAIA)

Conditions studied

Opioid Use Disorder — all drugs for Opioid Use Disorder →
Opioid Use Disorders — all drugs for Opioid Use Disorders →

Sponsor

University of Washington

Who can join

Adults 18 to 110, any sex, with Opioid Use Disorder or Opioid Use Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the effectiveness of a health systems strategy (the Systems Analysis and Improvement Approach - SAIA) that packages systems engineering tools (including cascade analysis, flow mapping, and continuous quality improvement) to optimize the management of opioid use disorder (MOUD) care cascade and improve linkages between jails and clinical referral sites. The investigators will 1. study the effectiveness of SAIA on MOUD care cascade quality and continuity for patients receiving care in jail and exiting to referral clinics 2. explore determinants of adoption, implementation, and sustainment of SAIA-MOUD across implementation clinics, and 3. estimate the cost and cost-effectiveness of SAIA-MOUD

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Systems analysis and improvement to optimize opioid use disorder care quality and continuity for patients exiting jail (SAIA-MOUD).
Gimbel S, Basu A, Callen E, Flaxman AD, et al · · 2024 · cited 1× · PMID 39696305 · DOI 10.1186/s13012-024-01409-0

Verify or expand the search:

Other trials of Systems Analysis and Improvement Approach (SAIA)

Trials testing the same drug.

NCT06747221 — Implementation Science to Enhance HIV Testing Services During Emergency Care in Kenya · NA · not yet recruiting
NCT05404958 — Systems Analysis and Improvement Approach to Improve Integration of HIV Prevention and Treatment Services · NA · recruiting
NCT03425136 — Systems Analysis and Improvement Approach for Prevention of MTC HIV Transmission · NA · completed

Other recruiting trials for Opioid Use Disorder

Currently open trials in the same condition.

NCT07278518 — Evaluation of a Patient Decision Aid for Emergency Department Initiated Buprenorphine · NA · recruiting
NCT07044466 — Social Functioning in Opioid Use Disorder · NA · recruiting
NCT07158853 — Combined tDCS and Cognitive Training as an Adjunctive Treatment in Opioid Use Disorder · NA · recruiting
NCT06943859 — Ketamine for Opioid Use Disorder · Phase 2 · recruiting
NCT06651177 — Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder · Phase 2 · recruiting

Other University of Washington trials

Trials by the same sponsor.

NCT07430852 — Inherited and Environmental Risks Acting on Body Weight · NA · not yet recruiting
NCT07466498 — Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Canc · Phase 2 · not yet recruiting
NCT06422299 — Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Youn · NA · not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06593353 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Washington
Last refreshed: 4 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06593353.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing